Role of tenascin С in triple-negative breast cancer

Abstract

Immunohistochemical analysis shows that the unique association between the CD44+/CD24low/- phenotype and the pronounced production of tenascin C may have a prognostic potential, prospectively indicating the inefficiency of neoadjuvant PCT, in particular that with platinum derivatives, which is used for the standard treatment of triple-negative BC. Taking into account the role of tenascin C in invasion, metastasis, and chemoresistance, it per se may be considered as a promising target for the targeted and/or combined therapy of triple-negative BC.